ISIN:FR0000032526

Guerbet: 2023 full-year results.

Retrieved on: 
Wednesday, April 10, 2024
CER, MRI, Guerbet, Growth, Medical imaging, Prostate, WCR, Software, IBM, Bank statement, IBM Watson, Iodine, Depreciation, NB, Liver, Artificial intelligence

The Group’s operating income came to €38.7m in 2023, compared with a loss of €18.2m the previous year.

Key Points: 
  • The Group’s operating income came to €38.7m in 2023, compared with a loss of €18.2m the previous year.
  • At 31 December 2023, Guerbet's net income stood at €22.2m, compared with a loss of €41.1m in 2022.
  • Free cash flow for full-year 2023 stood at -€65.4m, having entered positive territory in the second half at +€6.6m.
  • Financially, after comfortably achieving the business and profitability targets it had set for 2023, the Group is looking to 2024 with increased confidence.

Guerbet: Change in Guerbet’s Board of Directors.

Retrieved on: 
Wednesday, April 10, 2024
Financial management, Supervisory board, Trust, Central nervous system, Patient, GBT, Sanofi, Hospital, Mass meeting, Audit committee, MBA, OTC, BPI, Management

Guerbet: Change in Guerbet’s Board of Directors.

Key Points: 
  • Guerbet: Change in Guerbet’s Board of Directors.
  • Hugues Lecat’s appointment as a director will be submitted for approval at the next Shareholders’ Meeting.
  • The management experience acquired by Hugues in large companies in the pharmaceutical sector will help guide the Group in achieving further success.
  • Hugues was also a member of the Board of Directors of NOVASEP on behalf of BPI between 2012 and 2017.

Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.

Retrieved on: 
Wednesday, March 13, 2024
Senior, GBT, Corporate communication, Marketing, Commerce, Hemostasis, Government, Executive Committee, Thrombosis, Human resources, Public affairs, Communication, IVD

Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.

Key Points: 
  • Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
  • Villepinte, 11 march 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments.
  • Christine Allard and Eva Ohlsson have joined the Group as senior Vice-President Public Affairs and Corporate Communications, and Senior Vice President Human Resources respectively.
  • Reporting directly to David Hale, Chief Executive Officer, they will both become members of Guerbet’s Executive Committee.

Guerbet: 2023 revenue

Retrieved on: 
Thursday, February 8, 2024
Civil service commission, Acceleration, Growth, Medical imaging, European Commission, MRI, CER

The Diagnostic Imaging division posted revenue growth of 6.3 % at CER in 2023.

Key Points: 
  • The Diagnostic Imaging division posted revenue growth of 6.3 % at CER in 2023.
  • X-ray sales grew 7% in 2023 at CER, thanks to the robust sales trend of Xenetix®, which offset the decline in Optiray®revenues; this trend reversed in the fourth quarter of 2023, a period marked by growth for the entire X-ray division of 12.5% at CER.
  • For the 2023 financial year, after meeting its sales growth target, Guerbet will achieve a restated EBITDA margin rate3 higher than the 11% expected.
  • This objective is now largely supported by the favourable change in the product mix as well as cost control observed in the fourth quarter of 2023.

Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.

Retrieved on: 
Monday, February 5, 2024
Plant, Life, Family, Attitude, Death, Culture, Foot, Pharmaceutical industry

Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.

Key Points: 
  • Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
  • The Group is deeply saddened to announce the death of Michel Guerbet, who passed away on January 23, 2024 at the age of 92.
  • An historic figure in the Guerbet Group, Michel Guerbet was the son of André, who founded the laboratory in 1926, and the grandson of Marcel, who co-developed Lipiodol® in 1901.
  • The family is fully committed to supporting the Group in its operational development and the achievement of its medium- and long-term strategic objectives.